Quest Diagnostics Incorporated DGX
- Market cap
- $26.2B
- P/E
- 24.8×
Follow DGX
Quest Diagnostics Incorporated (DGX) Free cash flow
Quest Diagnostics Incorporated's free cash flow for fiscal 2025 was $1.4B, up 49.5% from $909.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.3B. Over the past ten years it has ranged from $558.0M (fiscal 2015) to $1.8B (fiscal 2021); the current reading is higher than 82% of that period. Quest Diagnostics Incorporated ranks 4th of 52 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.4B | 49.50% |
| FY2024 | $909.0M | 5.21% |
| FY2023 | $864.0M | (34.25%) |
| FY2022 | $1.3B | (28.20%) |
| FY2021 | $1.8B | 15.31% |
| FY2020 | $1.6B | 88.26% |
| FY2019 | $843.0M | 3.18% |
| FY2018 | $817.0M | (11.48%) |
| FY2017 | $923.0M | 12.15% |
| FY2016 | $823.0M | 47.49% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $459.0M | 179.88% |
| Mar 2026 | $164.0M | (46.58%) |
| Dec 2025 | $307.0M | (26.73%) |
| Sep 2025 | $419.0M | (3.90%) |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| DGX Quest Diagnostics Incorporated | $1.3B |
| IDXX IDEXX Laboratories, Inc. compare | $1.2B |
| LH Labcorp Holdings Inc. compare | $1.2B |
| ILMN Illumina, Inc. compare | $931.0M |
| MTD Mettler-Toledo International, Inc. compare | $864.0M |
| MEDP Medpace Holdings, Inc. compare | $706.7M |
| RVTY Revvity Inc. compare | $570.2M |
| WAT Waters Corporation compare | $366.6M |
| GH Guardant Health, Inc. compare | −$240.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on DGX
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement